Fluorescent humanized anti-CEA antibody specifically labels metastatic pancreatic cancer in a patient-derived orthotopic xenograft (PDOX) mouse model.

Abstract

Pancreatic cancer is a highly lethal disease in part due to incomplete tumor resection. Targeting by tumor-specific antibodies conjugated with a fluorescent label can result in selective labeling of cancer in vivo for surgical navigation. In the present study, we describe a patient-derived orthotopic xenograft model of pancreatic cancer that recapitulated the disease on a gross and microscopic level, along with physiologic clinical manifestations. We additionally show that the use of an anti-CEA antibody conjugated to the near-infrared (NIR) fluorescent dye, IRDye800CW, can selectively highlight the pancreatic cancer and its metastases in this model with a tumor-to-background ratio of 3.5 (SEM 0.9). The present results demonstrate the clinical potential of this labeling technique for fluorescence-guided surgery of pancreatic cancer.

• Authors: Thinzar M Lwin, Kentaro Miyake, Takashi Murakami, Jonathan C DeLong, Siamak Amirfakhri, Filemoni Filemoni, Sang Nam Yoon, Paul J Yazaki, John E Shivley, Brian Datnow, Bryan M Clary, Robert M Hoffman, Michael Bouvet
• Journal: Oncotarget (Oncotarget) Vol. 9 Issue 99 Pg. 37333-37342 (Dec 18 2018) ISSN: 1949-2553 [Electronic] United States
• PMID: 30647873 (Publication Type: Journal Article)